



FLUDARABINE

New PET lymphoma imaging application

[¹⁸F] Fludarabine has strong potential in PET imaging for detecting haematological malignancies, including lymphomas. This radiopharmaceutical can be used to visualise lymphoid tumour cells in situations where other diagnostic techniques remain limited in terms of specificity and sensitivity.


Carnot I2C Institute

Scientific / technological breakthrough

Preclinical and clinical trials involving [¹⁸F] Fludarabine, an innovative radiopharmaceutical for PET lymphoma imaging, have shown it to be more effective in terms of specificity and sensitivity than the equivalent standard radiotracer, [¹⁸F] FDG. Carnot I2C's LDM-TEP radiochemistry lab has filed a patent for [¹⁸F] Fludarabine imaging.



Automated radiosynthesis of Fludarabine



PET image of Fludarabine in a patient

Competitive advantage for the economic stakeholders

Interest in this molecule among the nuclear medicine community has led to national multi-centre clinical trials that aim to provide haematologists with new information to enhance the treatment and monitoring of patients with lymphoproliferative disorders.



Contact

Carnot I2C Institute - Cécile PERRIO - perrio@cyceron.fr et Fabienne GOURAND - gourand@cyceron.fr